Comparison of Autoantibodies Level in Thyroid Autoimmune Diseases Estimated by Different Methods

Summary

Autoantibodies to different thyroid cell components in serum of patients with thyroid disease have been estimated by several methods. The TSH receptor antibodies (TBAb) have been detected in 77% of untreated Graves-Basedow, in 70% of thionamide drugs treated Graves-Basedow patients up to four months of the treatment and in 48% of patients with Hashimoto's thyroiditis. Microsomal antibodies (MAb) and thyroid plasma membrane antibodies (ATMA) have been detected in 84% and 68% respectively, in thionamide drugs treated Graves-Basedow and in 91% and 72% in Hashimoto's thyroiditis. The thyroglobulin antibodies have been detected in 42% of untreated Graves-Basedow, in 47% of thionamide drugs treated Graves-Basedow and in 77% of Hashimoto's thyroiditis. In 19% to 21% of patients with toxic nodular goiter underlying autoimmunological process have been established by the detection of high levels of serum autoantibodies (ATMA and MAb). In the non-toxic nodular goiter, non-thyroid autoimmune diseases and healthy blood donors only thyroglobulin antibodies were detected in a significant number of patients. Other types of antibodies (ATMA or MAb) were detected only in sporadic cases of non-thyroid autoimmune diseases.

Key words

Thyroid autoimmune disease - Autoantibodies serum levels